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A b s t r a c t
Introduction: Prevention of peri- and postprocedural complications is still a challenge in carotid artery stenting (CAS).
Aim: To assess immediate and long-term safety and effectiveness of CAS using the Roadsaver double-nitinol-layer-micromesh 
stent.
Material and methods: Since 2014, 298 CAS procedures in 287 non-consecutive patients (203 men, mean age 70.5 ±8.6 years, 
100% symptomatic/high risk lesions) have been performed using the Roadsaver stent and proximal (40%) or distal (60%) neuropro-
tection system. Clinical and neurological examinations as well as duplex ultrasound were completed before CAS, before discharge, 
at 1, 6 and 12 months, then annually.
Results: All CAS procedures were successful. Carotid stenosis was reduced from 84.9 ±9.9% to 11.0 ±9.4% (p < 000.1). In hospi-
tal, 1 ipsilateral periprocedural major (0.3%) and 3 minor (1.34%) ischemic strokes occurred, 2 (0.7%) patients died due to a cerebral 
hemorrhage on day 9 and 21. Three (1.0%) additional ipsilateral minor strokes within 30 consecutive days occurred. Thus, 30-day 
complications were observed in 9 (3.0%) patients. Two minor strokes were associated with in-stent thrombosis (0.7%). The 4-year 
follow-up showed 82% overall survival (95% CI: 69–91%) with no significant difference between asymptomatic (77%) and symp-
tomatic patients (97%; p = 0.076). The stroke-free survival was 89% (95% CI: 77–95%), 84% asymptomatic vs. 98% symptomatic 
(p = 0.187). Seven (2.3%) patients developed > 50% in-stent restenosis.
Conclusions: Carotid artery stenting using the Roadsaver stent for symptomatic patients and high risk lesions showed to be 
safe and effective, with a low complication rate and acceptable in-stent restenosis risk in 4-year follow-up.
Key words: carotid artery stenting, Roadsaver stent, nitinol double-layer micromesh stent.
S u m m a r y
We aimed to assess immediate and long-term safety and effectiveness of carotid artery stenting (CAS) using the Road-
saver double-nitinol-layer-micromesh stent in 287 non-consecutive patients. All CAS were performed using the proximal 
(40%) or distal (60%) neuroprotection system. Clinical and neurological examination as well as duplex ultrasound were 
completed before CAS, before discharge, at 1, 6 and 12 months, then annually. All CAS procedures were successful. In 30 days 
major complications (stroke/death) were observed in 9 (3.0%) patients. The 4-year follow-up showed 82% overall survival 
with no significant difference between asymptomatic and symptomatic patients. The stroke-free survival was 89%. Seven 
(2.3%) patients developed > 50% in-stent restenosis.
Introduction
Effectiveness and safety of CAS as well as CEA in 
primary and secondary prevention of stroke have been 
demonstrated in high-volume cohorts of patients with 
carotid artery stenosis [1]. The CREST trial in patients 
with symptomatic and asymptomatic carotid artery 
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stenosis confirmed similar outcomes for CAS and CEA 
in the primary endpoint (stroke, death, myocardial in-
farction) but showed relative excess of minor stroke by 
30 days – mainly postprocedural – after CAS [2–4]. The 
risk of embolization as a  result of plaque protrusion 
and releasing debris is greatest after removal of an em-
bolic protection device (EPD) and persists for at least 
30 days until full endothelization of the stent [3–6]. It 
has been shown in several large-scale trials that the risk 
of releasing debris through the stent struts and distal 
embolization is significantly higher with open-cell stents 
as compared to closed-cell stents [3, 7, 8]. On the other 
hand, proper, individual-based selection of patients and 
wide use of proximal neuroprotection devices made it 
possible to achieve a complication rate of 1% if ‘small’ 
open-cell designed stents are in use for patients with tor-
tuous vessels and non-high-risk lesions [9]. In a search of 
compromise between open-cell and closed-cell designed 
stents, novel technology of stent architecture has been de-
veloped – by adding an extra micromesh layer to the stan-
dard open-cell or close-cell nitinol skeleton. Thus, it was 
possible to decrease the stent cell area to 0.38 mm² (Road-
saver, Terumo, Japan) or 0.15mm² (CGuard, InspireMD, Is-
rael). As this technology is relatively new there have been 
still concerns about the safety and long-term durability of 
dual layer micromesh-covered stents (DLMCS) in carotid 
artery stenting procedures. Some encouraging data on im-
mediate results of DLMCS implantation have already been 
collected [3, 10]. 
Aim
Assessment of immediate and long-term safety and 
efficacy of carotid artery stenting using Roadsaver stent 
in the treatment of symptomatic or high-risk, extracrani-
al carotid artery stenosis.
Material and methods
This is a retrospective analysis of 298 non-consecu-
tive DLMCS-supported CAS procedures in 287 patients 
(including 11 patients who underwent bilateral CAS) per-
formed between 2014 and 2019. All treated carotid le-
sions (> 50% in direct angiography by quantitative angiog-
raphy – QA) were symptomatic (89, 30%; ipsilateral stoke 
and/or transient ischemic attack in the last 6 months) 
or high-risk by morphology (209, 70%; echolucent, high-
ly lipidic, thrombus-containing, ulcerated and “string-
sign”) [11]. Most of the patients were men (203, 70.7%) 
and average age was 70.5 ±8.6 years (range: 51–88). 
Detailed group characteristics are provided in Table I.
In each patient routinely computed tomography (CT) 
scan of the head was performed as a part of indepen-
dent neurological evaluation before carotid intervention. 
The severity of stenosis (medial peak systolic velocity 
(PSV) of 3.77 ±1.7 m/s and end diastolic velocity (EDV) of 
1.32 ±0.56 m/s) and morphology of carotid plaque were 
evaluated by duplex Doppler ultrasonography (DUS) 
and/or CT. The target lesion was subsequently verified 
by direct quantitative angiography (QA) just before CAS. 
The angiographic diameter stenosis (DS) was 84.9 ±9.9% 
(range: 50–99%). 
All patients were on high-dose statin and dual an-
tiplatelet therapy (aspirin 75 mg daily and clopidogrel 
75 mg daily for at least 3 days before the procedure or 
loading dose of 300  mg of aspirin and clopidogrel the 
day before the procedure). During CAS unfractionated 
heparin (100 IU/kg) was used to achieve activating clot-
ting time in a range of 250–300 s. Atropine (1–2 mg i.v.) 
was administered just before stent implantation to avoid 
Table I. Baseline characteristics of patients
Parameter Value
Number of CAS 298
Number of patients 287





Active smokers 144 (50.2%)
Coronary artery disease* 177 (61.7%)
Previous myocardial infarction 74 (25.8%)
Previous CABG 35 (12.2%)
Previous percutaneous coronary artery intervention 97 (33.8%)
Glomerular filtration rate [ml/min/1.73 m2] 70.1 ±19.05
Previous  angioplasty in peripheral territory 29 (10.1%)
Previous surgical interventions in peripheral terri-
tory
9 (3.1%)
Contralateral ICA/CCA occlusion 24 (8.4%)
Contralateral ICA/CCA stenosis > 50% 32 (11.1%)
Symptomatic lesion® 89 (30%)
Asymptomatic lesion® 209 (70%)
Transient ischemic attack of ipsilateral hemisphere 
in the last 6 months
22 (7.7%)
Stroke of ipsilateral hemisphere in the last 6 months 57 (19.9%)
Ipsilateral amaurosis fugax in the last 6 months 10 (3.5%)
High risk lesionµ 237 (79.5%)
*Confirmed by angiography > 50% stenosis of at least one coronary artery or 
history of percutaneous coronary intervention (PCI) or coronary artery bypass 
graft (CABG), CABG – coronary artery bypass graft, ICA – internal carotid artery, 
CCA – common carotid artery, ®out of all 298 CAS procedures, µhigh risk lesion – 
echolucent, highly lipidic, ulcerated, “string-sign stenoses”, thrombus-contain-
ing lesions, ‘soft’ lesions, i.d. with computed tomography density of < 60 HU.
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a  severe baroreceptor response. Femoral (93.6%), right 
radial (5.7% ) or right brachial (0.7%) access was used. 
The detailed procedural steps including embolic protec-
tion device selection and pre/postdilatation balloon siz-
ing have been described previously [11]. The use of an 
embolic protection device (EPD) was mandatory. In 40.2% 
of patients proximal and in 59.7% of patients distal em-
bolic neuroprotection was applied. The devices used for 
CAS are presented in Table II. 
Direct stenting was performed in 132 (44.2%) cases 
whereas in 166 (55.7%) cases predilatation with a small 
coronary balloon (2.5–3.5 mm) was required. In all cases 
postdilatation was performed using usually 4.0–7.0 mm 
diameter balloons to optimize the angiographic outcome. 
In each patient angiography of intracranial arteries before 
and comparatively after the procedure was performed. 
The most representative examples of DLMCS-supported 
CAS are shown in Figures 1 and 2. 
Patients were discharged 1–2 days after procedure 
completion with the recommendation of continua-
tion of aspirin, statin (indefinitely) and clopidogrel (for 
3 months). In 35 patients with atrial fibrillation vitamin K 
antagonists or novel oral anticoagulants were restarted 
after CAS. As the risk of in-stent restenosis is highest 
Table II. The devices utilized during CAS
Proximal embolic protection devices:
(Femoral access)
– MonoMo.Ma 8Fr (n = 1)
– Mo.Ma 9 Fr (n = 2)
– Mo.Ma 8Fr (n = 118)
Distal embolic protection devices:
(Femoral access or right radial or right brachial access)
– Wirion (n = 9)
– Filter Wire EZ (n = 19)
– Emboshield NAV (n = 61)
– Spider FX (n = 88)
Predilatation (n = 166):
– Sizes of balloon catheter: diameter of 2.0–4.0 mm, 15–30 mm in length 
– Inflation pressure: 10–20 atm
Sizes of Roadsaver stents: size 6–10 mm diameter, length 18–40 mm (the most commonly used: size 9.0 × 20 mm in 20.1%, 8.0 × 25 mm in 
18.1%, 8.0 × 20 mm in 15.4%)
Postdilatation (n = 298):
– Sizes of balloon catheter: diameter of 4.0–7.0 mm, 15–30 mm in length 
– Inflation pressure: 8–20 atm
Figure 1. CAS of severe, high risk stenosis of right ICA using Roadsaver stent and Mo.Ma EPD: A – angiography 
– 90% RICA stenosis, B – Mo.Ma distal balloon inflated in external carotid artery, C – Both balloons of Mo.Ma 
system inflated, predilatation with 2.5 × 25 mm balloon, D – 8.0 × 25 mm Roadsaver stent implantation,  
E – postdilatation with 5.0 × 20 mm balloon, F – final angiography showing optimal angiographic result of CAS
A B C D E F
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in the first year after the initial procedure, clinical and 
neurological evaluation as well as DUS examination were 
performed before discharge, after 30 days, 6 months, 
12 months and every year afterwards [11, 12].
Statistical analysis
Categorical variables are presented as numbers and 
percentages. Continuous variables were expressed as 
mean and standard deviation (SD). Comparison between 
baseline and post-procedural results (including follow-up 
assessments) of %DS, PSV and EDV values were per-
formed using the Wilcox signed-rank test. The log-rank 
statistic was used to test the differences between symp-
tomatic and asymptomatic subjects. Survival curves were 
calculated using the Kaplan-Meier method. Two-sided 
p-values < 0.05 were considered statistically significant. 
All calculations were done with JMP, Version 14.2.0 (SAS 
Institute INC., Cary, NC, USA) and using R, Version 3.4.1 
(R Core Team. R: A language and environment for statis-
tical computing. R Foundation for Statistical Computing. 
Vienna, Austria, 2017). 
Results
The Roadsaver stent was successfully delivered and 
expanded in all cases. The postprocedural residual steno-
sis was 0–33% by QA (mean: 11.03 ±9.4%) vs. 84.9 ±9.9% 
(range: 50–99%) before the procedure (p < 0.001). Con-
trol DUS evaluation at 24–48 h after stenting revealed 
a  significant PSV/EDV decrease as compared to initial 
values (1.3/0.31 ±0.35/0.11 m/s vs. 3.77/1.32 ±1.7/0.56 
m/s respectively; p < 0.0001). Mean PSV/EDV values were 
1.2/0.34 ±0.58/0.16 m/s at 30 days, 1.2/0.4 ±0.4/0.1 m/s 
at 6 months, 1.3/0.5 ±0.4/1.7 m/s at 12 months, 1.3/0.4 
±0.4/0.1 m/s at 24 months, 1.29/0.38 ±0.38/0.1 m/s at 
36 months and 1.35/0.40 ±0.35/0.10 at 48 months.
During hospitalization one ipsilateral major and three 
minor (NIHSS < 5 points [12]) ischemic strokes occurred 
(1.34%), and 1 (0.3%) patient died due to hemorrhagic 
stroke. Between discharge and 30 days 1 (0.3%) patient 
died due to hemorrhagic stroke and 3 (1.0%) ipsilateral 
minor strokes occurred – of those 2 were associated with 
in-stent thrombosis (0.7%). Thus, the 30-day complica-
tion rate was 3.02% (n = 9).
Among patients who died due to hemorrhagic stroke, 
one case was a  consequence of hyperperfusion syn-
drome (HPS) that occurred 2 days after CAS; the other 
cause of death has remained unknown and it occurred 
21 days after CAS. 
Both patients with stent thrombosis were on recom-
mended medications, including dual antiplatelet thera-
py. The first case of in-stent thrombosis occurred 5 days 
after CAS in a  76-year-old man, within a  8.0 × 25 mm 
Figure 2. Severe symptomatic lesion of the left ICA and the subsequent steps of CAS using Roadsaver stent 
and distal EPD-SpiderFX 7 mm, right radial access: A – angiography showing 90% LICA stenosis, B – opening 
of the filter in the distal segment of LICA (arrow) and predilatation with 3.0 × 15 mm balloon, C – 7.0 × 18 mm 
Roadsaver stent implantation, D – postdilatation with 5.0 × 20 mm balloon, E – final angiography showing 
optimal angiographic result of CAS
A B C D E
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stent, and led to total artery occlusion and minor stroke. 
The second thrombosis occurred 14 days after CAS in 
a 67-year-old man, within a 9.0 × 20 mm stent, and led 
to subtotal (99%) artery stenosis and minor stroke. Neu-
rological symptoms receded and the thrombus was dis-
solved within 24 h after introduction of continuous i.v. 
heparin. Additionally, resistance to clopidogrel was diag-
nosed and the patient was switched to ticagrelor without 
further signs of recurrent thrombosis.
One and six months DUS follow-up did not show fur-
ther in-stent thrombus formation.
Eighteen patients died during 4 years of follow-up 
(6.3%). Of those, 10 (3.5%) patients died due to cardio-
vascular complications (myocardial infarction/sudden 
cardiac death (n = 9), heart failure (n = 1)), and 2 (0.7%) 
patients died due to ischemic stroke 33 months and 
37 months after CAS. In 6 (2.1%) patients the cause of 
death remains unknown. Excluding in-stent thrombosis 
cases, in all stroke patients normal in-stent blood flow 
was assessed by DUS.
The 4-year follow-up showed 82%/89% overall sur-
vival/stroke-free survival with no significant difference 
between symptomatic and asymptomatic patients (Fig-
ures 3 and 4).
Eleven patients could not be contacted; thus, the 
lost-to-follow-up rate was 3.8%.
Seven (2.3%) cases of in stent restenosis were ob-
served in a  period 5–12 months after CAS, 4 patients 
underwent successful re-angioplasty using drug-elut-
ing balloons (DEB), 2 cases required self-expandable 
drug-eluting stent implantation, and in one asymptom-
atic patient re-angioplasty failed due to a problem with 
Figure 4. Four-year Kaplan-Meier stroke free-survival curves for patients undergoing carotid artery stenting 
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Figure 3. Four-year Kaplan-Meier event free-survival curves for patients undergoing carotid artery stenting with 
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vascular access (Leriche syndrome and unsuccessful ra-
dial/brachial access attempt). As the patient was asymp-
tomatic he was qualified for optimal medical treatment.
Discussion
Technological development is an on-going process. 
Despite the fact that the majority of stents implanted in 
the CREST study population were open-cell with single 
cell area of 11.5 mm2, the 30-day results were similar to 
those of the gold standard CEA [3]. As it was previously 
pointed out, plaque protrusion is an important handicap 
of first generation stents and may significantly increase 
the risk of distal embolization. In 2013 a new family of 
double-layer micromesh-covered stents was introduced. 
The technology, combining the architecture of open-cell 
stents (providing optimal flexibility and apposition) with 
closed cells of micromesh (0.381 mm2, 375–500 µm Road-
saver or 0.15 mm2, 150–180 µm, CGuard) opened the 
way to perform CAS offering full anatomical restoration 
of the vessel and optimal protection against plaque pro-
trusion and distal embolization [2, 10]. Indeed, data on 
optical coherence tomography (OCT) and IVUS confirm 
Roadsaver stent optimal wall apposition with no signifi-
cant plaque protrusion through stent cells [2, 3, 13–15]. 
Moreover, the diffusion-weighed magnetic resonance 
imaging (DW-MRI) studies showed low, clinically insig-
nificant intracerebral embolization within 24–48 h after 
CAS and no new spots of embolization within the next 
30 days [16, 17]. The very low complication rate of 1% 
was confirmed by the results of several studies including 
a total of 550 patients who underwent CAS with implan-
tation of a dual-layer micromesh covered stent (Roadsav-
er or CGuard) [3, 18–21]. On the other hand, it has been 
widely discussed that distal embolization may occur at 
each step of the procedure; thus, the right selection of 
neuroprotection device is also crucial [11, 22]. Montor-
si et al. compared recently the Roadsaver stent with the 
Carotid Wallstent (single-layer, closed-cell design; Boston 
Scientific, US) in association with either distal embolic 
protection (FilterWire EZ, Boston Scientific, US) or prox-
imal embolic protection (Mo.Ma, Medtronic, Italy) in pa-
tients with high-risk lipid-rich carotid plaques [23]. CAS 
performed with the Mo.Ma system gave significantly less 
microembolic signals in transcranial DUS when combined 
with the Roadsaver as opposed to the Carotid Wallstent 
p = 0.043). It is also very important that the clear benefit 
of using the Mo.Ma device was seen when study pop-
ulation was divided into two groups according to type 
of neuroprotection use – the Mo.Ma system significantly 
reduced the mean microembolization signal count during 
consecutive steps of CAS (lesion crossing, stent crossing, 
stent deployment and post-dilation) on transcranial DUS. 
There have been some concerns raised over in-Road-
saver-stent thrombosis. Yilmaz et al. performed a retro-
spective analysis of data concerning intracranial inter-
ventions in the treatment of acute stroke associated with 
dual-layer micromesh-covered stent CAS and reported 
a higher risk of acute thrombosis [24]. Although in the 
study the Roadsaver stent had a significantly higher rate 
of acute occlusion as compared with the Carotid Wall-
stent (p = 0.001), there might have been some imbal-
ance between the study groups, e.g. significantly more 
patients from the group of single-layer stent received 
recombinant tissue plasminogen activator before the 
procedure and a group of patients with acute stent oc-
clusion had a trend to be treated with smaller stent di-
ameters and had a  higher platelet count. The authors 
did not give information about intraprocedural heparin 
use and not all patients received dual antiplatelet ther-
apy. Another example of acute thrombosis in DLMCS is 
given by Casana et al., who describe CGuard stent oc-
clusion 4 h after implantation to the extracranial part of 
the internal carotid artery [22]. We registered two cas-
es (0.7%) of thrombosis in our center – at days 5 and 
12 after the procedure. The thrombosis clinically pre-
sented as minor strokes. Although it seems that acute 
in-Roadsaver stent thrombosis is a  rare phenomenon, 
data on long-term follow-up are not yet available. It is 
important to note that patients from our registry were 
symptomatic or with high risk lesions [11], with gener-
alized and advanced atherosclerosis. These factors may 
also influence the risk of periprocedural complications 
including cerebral embolization. Another important fact 
is that both ends of the Roadsaver stent are not covered 
with a dual-layer micromesh layer. If the atherosclerotic 
plaque is not completely covered by a  micromesh part 
of the stent (e.g. in severe, disseminated atherosclero-
sis), there is a risk of plaque mobilization and protrusion. 
Total death/stroke/myocardial infarction in 30-day fol-
low-up in our center was 3.0% in total, 1.2% in symp-
tomatic and 3.8% in asymptomatic (but with high-risk 
lesions) patients. Although the complication rate for the 
asymptomatic group slightly exceeds the threshold of 
3% accepted by guidelines, it is important to remember 
that all those patients had high-risk carotid artery steno-
sis (i.e. echolucent, highly lipidic, ulcerated, “string-sign 
stenoses”, thrombus-containing, ‘soft’ lesions). High-risk 
plaque has been shown to be associated directly with 
high risk of embolization during CAS performed using 
a conventionally designed stent and distal neuroprotec-
tion [25, 26].
It should also be emphasized that the technical suc-
cess, periprocedural complications and treatment out-
comes depend not only on access to innovative technol-
ogy and proper selection of patients; the learning curve 
in CAS procedures cannot be neglected [27].
Although it is still an early period of observation, 
our work has shown that the risk of significant in-Road-
saver-stent restenosis remains in the acceptable range 
during 4-year follow-up (2.3% as compared to 6.0% 
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reported by CREST investigators [28]). Importantly, it 
might be presumed that non-mandatory postdilatation 
in CREST may have influenced the results. However, in 
comparison to the smallest-cell design Carotid Wallstent 
postdilated obligatorily with a 4.5–5.5 mm balloon, still 
the Roadsaver shows much lower prevalence of reste-
nosis [29].
As the Roadsaver low profile makes both femoral and 
radial/brachial access available there was no need for 
use of direct carotid hybrid surgical/endovascular access 
in our cohort. Even so, it has been demonstrated that di-
rect transcervical access for carotid artery stenting is safe 
and effective, and may be considered in patients with 
unfavorable anatomy [30].
There are some limitations of our research. It was 
a non-randomized study in selected patients. No pre- or 
post-procedural diffusion-weighed magnetic resonance 
cerebral imaging was performed to determine the true 
number of cases of cerebral embolization. There was no 
intravascular imaging assessing the local effect of stent 
implantation. 
Conclusions
CAS using the Roadsaver stent for symptomatic and 
high risk lesions seems to be safe and effective, with 
a low complication rate and acceptable in-stent resteno-
sis risk in 4-year follow-up.
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